Nevo on track for European release after trial posts positive twelve-month data
This article was originally published in Clinica
Executive Summary
The latest results from the RES I trial of Cordis's Nevo drug-eluting stent (DES) indicate that the device is safer than Boston Scientific's Taxus Liberté DES a year after implantation.
You may also be interested in...
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Normality Reasserts Itself For Biotech IPOs
The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.
MRM Health Pulls A Pouchitis Hit Out Of The Bag
The mid-stage success is encouraging, but taking on Takeda won’t be easy.